UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.133

Sortiert nach

Pharmacokinetics of EDP-420 after Multiple Oral Doses in Healthy Adult Volunteers and in a Bioequivalence Study

Antimicrobial Agents and Chemotherapy, 2009-08, Vol.53 (8), p.3218-3225

2009

Link zum Volltext

Verfügbarkeit prüfen

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

Liver international, 2020-07, Vol.40 (7), p.1655-1669

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of EDP-420 after Ascending Single Oral Doses in Healthy Adult Volunteers

Antimicrobial Agents and Chemotherapy, 2009-05, Vol.53 (5), p.1786-1792

2009

Link zum Volltext

Verfügbarkeit prüfen

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model

PLoS pathogens, 2021-03, Vol.17 (3), p.e1009428-e1009428

2021

Link zum Volltext

Verfügbarkeit prüfen

P44 - Tissue distribution of EDP-305, a highly selective and potent farnesoid X receptor (FXR) agonist, in preclinical species

Drug metabolism and pharmacokinetics, 2020, Vol.35 (1), p.S34-S34

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist

Hepatology communications, 2018-07, Vol.2 (7), p.821-835

2018

Link zum Volltext

Verfügbarkeit prüfen

Design, synthesis, and antibacterial activities of novel 3,6-bicyclolide oximes: Length optimization and zero carbon linker oximes

Bioorganic & medicinal chemistry, 2008-09, Vol.18 (18), p.5078-5082

2008

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of 3,6-bicyclolides: A novel class of macrolide antibiotics

Bioorganic & medicinal chemistry, 2008-12, Vol.18 (24), p.6315-6318

2008

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of Novel 6,11-O-Bridged Bicyclic Ketolides via a Palladium-Catalyzed Bis-allylation

Organic letters, 2004-11, Vol.6 (24), p.4455-4458

2004

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Antibacterial Activity of a Novel Class of 4‘-Substituted 16-Membered Ring Macrolides Derived from Tylosin

Journal of medicinal chemistry, 2004-06, Vol.47 (12), p.2965-2968

2004

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Antimicrobial Activity of 6-O-Substituted Ketolides Active against Resistant Respiratory Tract Pathogens

Journal of medicinal chemistry, 2000-03, Vol.43 (6), p.1045-1049

2000

Link zum Volltext

Verfügbarkeit prüfen

Su1502 - EDP-305, a Selective Farnesoid X Receptor Agonist, Exhibits Excellent Potency In Vitro and In Vivo and Anti-Fibrotic Effect In Vitro

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1159-S-1159

2018

Link zum Volltext

Verfügbarkeit prüfen

Su1498 - A Highly Selective and Potent Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity (NAS) in two Murine Models of Non-Alcoholic Steatohepatitis (NASH)

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-1159-S-1159

2018

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450

Antimicrobial agents and chemotherapy, 2015-02, Vol.59 (2), p.988-997

2015

Link zum Volltext

Verfügbarkeit prüfen

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

Antimicrobial agents and chemotherapy, 2018-01, Vol.62 (1)

2018

Link zum Volltext

Verfügbarkeit prüfen

FRI-356 - HSD17B13 inhibitors are hepatoprotective and anti-inflammatory in a mouse model of autoimmune hepatitis

Journal of hepatology, 2023-06, Vol.78, p.S422-S422

2023

Link zum Volltext

Verfügbarkeit prüfen

HSD17B13 inhibitors are hepatoprotective and anti-inflammatory in a mouse model of autoimmune hepatitis

Journal of hepatology, 2023-06, Vol.78, p.S422

2023

Link zum Volltext

Verfügbarkeit prüfen

SAT042 - A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and rodent NASH and liver injury models

Journal of hepatology, 2020-08, Vol.73, p.S672-S672

2020

Link zum Volltext

Verfügbarkeit prüfen

A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and rodent NASH and liver injury models

Journal of hepatology, 2020-08, Vol.73, p.S672

2020

Link zum Volltext

Verfügbarkeit prüfen

Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma

The Turkish journal of gastroenterology, 2023-06, Vol.34 (6), p.635-644

2023

Link zum Volltext

Verfügbarkeit prüfen

923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study

Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic inhibition of HSD17B13 is hepatoprotective in mouse models of liver injury

Journal of hepatology, 2022-07, Vol.77, p.S745-S746

2022

Link zum Volltext

Verfügbarkeit prüfen

Molecular Basis for Antiviral Action of EDP‐235: A Potent and Selective SARS‐CoV‐2 3CLpro Inhibitor for the Treatment of Covid 19

The FASEB journal, 2022-05, Vol.36 (S1), p.n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and Biological Evaluation of Novel Cyclosporin A Analogues: Potential Soft Drugs for the Treatment of Autoimmune Diseases

Journal of medicinal chemistry, 2003-02, Vol.46 (5), p.674-676

2003

Link zum Volltext

Verfügbarkeit prüfen

FRI109 - EDP-297, a novel and potent fxr agonist, exhibit robust anti-fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis

Journal of hepatology, 2020-08, Vol.73, p.S453-S453

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(872)
Mit Volltextzugriff
(1.076)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Pharmacokinetics of EDP-420 after Multiple Oral Doses in Healthy Adult Volunteers and in a Bioequivalence Study

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

Pharmacokinetics of EDP-420 after Ascending Single Oral Doses in Healthy Adult Volunteers

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model

P44 - Tissue distribution of EDP-305, a highly selective and potent farnesoid X receptor (FXR) agonist, in preclinical species

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist

Design, synthesis, and antibacterial activities of novel 3,6-bicyclolide oximes: Length optimization and zero carbon linker oximes

Synthesis of 3,6-bicyclolides: A novel class of macrolide antibiotics

Synthesis of Novel 6,11-O-Bridged Bicyclic Ketolides via a Palladium-Catalyzed Bis-allylation

Synthesis and Antibacterial Activity of a Novel Class of 4‘-Substituted 16-Membered Ring Macrolides Derived from Tylosin

Design, Synthesis, and Antimicrobial Activity of 6-O-Substituted Ketolides Active against Resistant Respiratory Tract Pathogens

Su1502 - EDP-305, a Selective Farnesoid X Receptor Agonist, Exhibits Excellent Potency In Vitro and In Vivo and Anti-Fibrotic Effect In Vitro

Su1498 - A Highly Selective and Potent Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity (NAS) in two Murine Models of Non-Alcoholic Steatohepatitis (NASH)

In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir

FRI-356 - HSD17B13 inhibitors are hepatoprotective and anti-inflammatory in a mouse model of autoimmune hepatitis

HSD17B13 inhibitors are hepatoprotective and anti-inflammatory in a mouse model of autoimmune hepatitis

SAT042 - A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and rodent NASH and liver injury models

A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and rodent NASH and liver injury models

Fibulin-2 Facilitates Malignant Progression of Hepatocellular Carcinoma

923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study

Pharmacologic inhibition of HSD17B13 is hepatoprotective in mouse models of liver injury

Molecular Basis for Antiviral Action of EDP‐235: A Potent and Selective SARS‐CoV‐2 3CLpro Inhibitor for the Treatment of Covid 19

Synthesis and Biological Evaluation of Novel Cyclosporin A Analogues: Potential Soft Drugs for the Treatment of Autoimmune Diseases

FRI109 - EDP-297, a novel and potent fxr agonist, exhibit robust anti-fibrotic effects with significant liver function in a rat model of non-alcoholic steatohepatitis

Suchergebnisse filtern